To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
Merck and Intercell AG have announced that following a pre‐specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.
Although the trial did not meet the pre‐specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
